Nancy Cross

792 citations
20 papers · 421 · h-index 6

Impact in

  • Dermatology top 2%
    • Dermatology and Skin Diseases
  • Immunology top 10%
    • Psoriasis: Treatment and Pathogenesis
    • Immunodeficiency and Autoimmune Disorders

Papers in

Co-authors
Christopher L. Cioffi (8 shared papers)Andrew Blauvelt (8 shared papers)Kim Papp (7 shared papers)Luke Peterson (7 shared papers)Joseph F. Merola (10 shared papers)Alice B. Gottlieb (10 shared papers)C.E.M. Griffiths (5 shared papers)Richard B. Warren (5 shared papers)
Journals
Journal of the American Academy of Dermatology (6 papers)The Philosophical Magazine A Journal of Theoretical Experimental and Applied Physics (1 paper)Dermatology and Therapy (1 paper)Journal of Physics Condensed Matter (1 paper)New England Journal of Medicine (1 paper)
Partner nations
United StatesUnited KingdomBelgium

In The Last Decade

Nancy Cross

18 papers receiving 416 citations

Peers

Nancy Cross
Comparison fields: 5 of 53
  • Dermatology 209
  • Immunology 367
  • Rheumatology 85
  • Hematology 54
  • Pathology and Forensic Medicine 70
Replace Jolanta Węgłowska with:
Jolanta Węgłowska Poland
Katherine Armour Australia
Gustavo Añez Sturchio Spain
Guifen Shen China
Nicole Selenko-Gebauer Austria
Stanton K. Wesson United States
Tejaswi Mudigonda United States
Youngdoe Kim South Korea
Mario Aricò Italy
Anurag Bhalla Canada
Nancy Cross relative to Jolanta Węgłowska Poland Jolanta Węgłowska's profile →
Citations per field
00.5×2×3×3.5×
Jolanta Węgłowska · 1×
Citations per year

Countries citing papers authored by Nancy Cross

Since Specialization
Citations

This map shows the geographic impact of Nancy Cross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancy Cross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancy Cross more than expected).

Fields of papers citing papers by Nancy Cross

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nancy Cross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancy Cross. The network helps show where Nancy Cross may publish in the future.

Co-authors

The 25 scholars most cited alongside Nancy Cross, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Nancy Cross Line = papers co-authored together Nancy Cross links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
Journal of the American Academy of Dermatology ·Kim Papp, Joseph F. Merola, Alice B. Gottlieb, C.E.M. Griffiths, Nancy Cross, Luke Peterson, Christopher L. Cioffi, Andrew Blauvelt
2018157
2
Bimekizumab versus Adalimumab in Plaque Psoriasis
New England Journal of Medicine ·Richard B. Warren, Andrew Blauvelt, Jerry Bagel, Kim Papp, Paul S. Yamauchi, April W. Armstrong, Richard G. Langley, Veerle Vanvoorden, Dirk De Cuyper, Christopher L. Cioffi, Luke Peterson, Nancy Cross, Kristian Reich
2021139
3
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study
Journal of the American Academy of Dermatology ·Andrew Blauvelt, Kim Papp, Joseph F. Merola, Alice B. Gottlieb, Nancy Cross, Cynthia Madden, Maggie Haitian Wang, Christopher L. Cioffi, C.E.M. Griffiths
202050
4
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis
JAMA Dermatology ·Kenneth B. Gordon, Richard G. Langley, Richard B. Warren, Yukari Okubo, Linda Stein Gold, Joseph F. Merola, Luke Peterson, Krista Wixted, Nancy Cross, Delphine Deherder, Diamant Thaçi
202236
5
Structure and reactivity of Bi allotropes on the fivefold icosahedral Al–Pd–Mn quasicrystal surface
Journal of Physics Condensed Matter ·J. A. Smerdon, Nancy Cross, V.R. Dhanak, H. R. Sharma, K. M. Young, T. A. Lograsso, A. R. Ross, R. McGrath
201012
6
27380 Bimekizumab efficacy in patients with moderate to severe plaque psoriasis during the randomized withdrawal and retreatment phase of BE READY, a phase 3 trial
Journal of the American Academy of Dermatology ·Andrew Blauvelt, Jashin J. Wu, Kristian Reich, Melinda Gooderham, Mark Lebwohl, Katy White, Nancy Cross, Christopher L. Cioffi, Kim Papp
20216
7
XPS study of adsorption and desorption of a Bi thin film on the five-fold icosahedral Al-Pd-Mn surface
The Philosophical Magazine A Journal of Theoretical Experimental and Applied Physics ·K. M. Young, Nancy Cross, J. A. Smerdon, V.R. Dhanak, H. R. Sharma, T. A. Lograsso, A. R. Ross, R. McGrath
20114
8
Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials
Dermatology and Therapy ·Joseph F. Merola, Alice B. Gottlieb, Andreas Pinter, Boni E. Elewski, Melinda Gooderham, Richard B. Warren, Stefano Piaserico, Krista Wixted, Nancy Cross, Nicola Tilt, Susanne Wiegratz, Ulrich Mrowietz
20242
9
14020 Durability of responses with bimekizumab, a selective dual inhibitor of interleukin-17A and -17F, in moderate to severe chronic plaque psoriasis in a 60-week randomized, double-blinded, phase 2b study (BE ABLE 2)
Journal of the American Academy of Dermatology ·Andrew Blauvelt, Joseph F. Merola, Kim Papp, Melinda Gooderham, Alice B. Gottlieb, Christopher L. Cioffi, Luke Peterson, Nancy Cross, C.E.M. Griffiths, Diamant Thaçi
20202
10
The effects of N-methyl-d-aspartate (NMDA) and non-NMDA receptor agonist and antagonists on hypothalamic neurones in the anaesthetized rat which respond to changes in scrotal skin temperature
Neuroscience Letters ·David C. Taylor, R.J. Gayton, Helen E. Miley, Nancy Cross, M.P. Parton
19952
11
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials
Journal of the American Academy of Dermatology ·Mark Lebwohl, Joseph F. Merola, Bruce Strober, April W. Armstrong, Ayumi Yoshizaki, Paolo Gisondi, Balint Szilagyi, Luke Peterson, Dirk De Cuyper, Nancy Cross, O. Davies, Alice B. Gottlieb
20242
12
AB0738 DUAL NEUTRALISATION OF INTERLEUKIN (IL)–17A AND IL–17F WITH BIMEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 60-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLINDED, PHASE 2B EXTENSION STUDY
Annals of the Rheumatic Diseases ·Andrew Blauvelt, Kim Papp, Joseph F. Merola, Alice B. Gottlieb, Nancy Cross, Cynthia Madden, Maggie Haitian Wang, Christopher L. Cioffi, C.E.M. Griffiths
20192
13
Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)
SKIN The Journal of Cutaneous Medicine ·Richard B. Warren, Andrew Blauvelt, Jerry Bagel, KA Papp, Paul S. Yamauchi, April W. Armstrong, Richard G. Langley, Veerle Vanvoorden, Dirk De Cuyper, Luke Peterson, Nancy Cross, Kristian Reich
20212
14
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
Journal of the American Academy of Dermatology ·(unknown), Richard G. Langley, Mark Lebwohl, Bruce Strober, Richard B. Warren, L. Puig, Akimichi Morita, Kenneth B. Gordon, Pablo Fernández‐Peñas, Sarah Kavanagh, José M. López Pinto, Jérémy Lambert, Bengt Hoepken, Delphine Deherder, Nancy Cross, Diamant Thaçi
20251
15
Bimekizumab 3-year Efficacy in High-Impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from Five Phase 3/3b Trials
SKIN The Journal of Cutaneous Medicine ·Joseph F. Merola, Curdin Conrad, Philip Hampton, Jo Lambert, Alice B. Gottlieb, Nicola Tilt, Nancy Cross, Susanne Wiegratz, Melinda Gooderham
20241
16
Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension
SKIN The Journal of Cutaneous Medicine ·Diamant Thaçi, Ronald Vender, Menno De Rie, Curdin Conrad, Jennifer Soung, Bruce Strober, Maggie Haitian Wang, Nancy Cross, Delphine Deherder, Natalie Núnez Gómez, Alice B. Gottlieb
20221
17
Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study
SKIN The Journal of Cutaneous Medicine ·Andrew Blauvelt, Kim Papp, Joseph F. Merola, Alice B. Gottlieb, Nancy Cross, Cindy Madden, Luke Peterson, Christopher L. Cioffi, C.E.M. Griffiths
20191
18
Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials
SKIN The Journal of Cutaneous Medicine ·Mark Lebwohl, April W. Armstrong, Joseph F. Merola, Alice B. Gottlieb, Leah Davis, Braulio Gómez, Susanne Wiegratz, Nancy Cross, Bruce Strober
20221
19
Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo‐controlled, double‐blinded study
The Journal of Dermatology ·Sang Woong Youn, Seong Jin Jo, Chul Jong Park, Dong Hyun Kim, Bong Seok Shin, Ki‐Heon Jeong, Chul Hwan Bang, Nancy Cross, J. Thirlwell, Bengt Hoepken
20240
20
Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial
SKIN The Journal of Cutaneous Medicine ·Bruce Strober, Akihiko Asahina, Ulrich Mrowietz, Mark Lebwohl, Peter Foley, Richard G. Langley, Juliet N. Barker, Christopher L. Cioffi, Nancy Cross, Maggie Haitian Wang, C. Paul
20210

About Nancy Cross

Nancy Cross is a scholar working on Immunology, Pathology and Forensic Medicine, Dermatology, Pediatrics, Perinatology and Child Health and Hematology, having authored 20 papers that have together received 421 indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (17 papers), Autoimmune Bullous Skin Diseases (8 papers), Dermatology and Skin Diseases (4 papers), Chronic Myeloid Leukemia Treatments (3 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers), Pharmaceutical studies and practices (3 papers), Mast cells and histamine (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). The work is most often cited by research in Dermatology (209 citations), Immunology (367 citations), Rheumatology (85 citations), Hematology (54 citations) and Pathology and Forensic Medicine (70 citations). Nancy Cross has collaborated with scholars based in United States, United Kingdom and Belgium. Frequent co-authors include Christopher L. Cioffi, Andrew Blauvelt, Kim Papp, Luke Peterson, Joseph F. Merola, Alice B. Gottlieb, C.E.M. Griffiths, Richard B. Warren, Richard G. Langley and Kristian Reich. Their work appears in journals such as Journal of the American Academy of Dermatology, The Philosophical Magazine A Journal of Theoretical Experimental and Applied Physics, Dermatology and Therapy, Journal of Physics Condensed Matter and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jolanta WęgłowskaBreakdown of academic impact, for papers by Katherine ArmourBreakdown of academic impact, for papers by Gustavo Añez SturchioBreakdown of academic impact, for papers by Guifen ShenBreakdown of academic impact, for papers by Nicole Selenko-GebauerBreakdown of academic impact, for papers by Stanton K. WessonBreakdown of academic impact, for papers by Tejaswi MudigondaBreakdown of academic impact, for papers by Youngdoe KimBreakdown of academic impact, for papers by Mario AricòBreakdown of academic impact, for papers by Anurag Bhalla